Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers

被引:32
|
作者
Callahan, Brandy L. [1 ,2 ,3 ,4 ,5 ]
Ramirez, Joel [1 ,2 ,3 ]
Berezuk, Courtney [1 ,2 ,3 ]
Duchesne, Simon [4 ,5 ]
Black, Sandra E. [1 ,2 ,3 ,6 ]
机构
[1] Sunnybrook Hlth Sci Ctr, LC Campbell Cognit Neurol Res Unit, 2075 Bayview Ave,Rm A4 21, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Canadian Partnership Stroke Re, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook Res Inst, Brain Sci Res Program, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Univ Laval, Fac Med Radiol, Quebec City, PQ, Canada
[5] Inst Univ Sante Mentale Quebec, Ctr Rech, Quebec City, PQ, Canada
[6] Univ Toronto, Inst Med Sci, Dept Med Neurol, Quebec City, PQ, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
IMPAIRMENT; ATROPHY; RECOMMENDATIONS; DEMENTIA; MARKERS; AGE;
D O I
10.1186/s13195-015-0152-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The definition of "objective cognitive impairment" in current criteria for mild cognitive impairment (MCI) varies considerably between research groups and clinics. This study aims to compare different methods of defining memory impairment to improve prediction models for the development of Alzheimer's disease (AD) from baseline to 24 months. Methods: The sensitivity and specificity of six methods of defining episodic memory impairment (< -1, -1.5 or -2 standard deviations [SD] on one or two memory tests) were compared in 494 non-demented seniors from the Alzheimer's Disease Neuroimaging Initiative using the area under the curve (AUC) for receiver operating characteristic analysis. The added value of non-memory measures (language and executive function) and biomarkers (hippocampal and white-matter hyperintensity volume, brain parenchymal fraction [BPF], and APOE epsilon 4 status) was investigated using logistic regression. Results: Baseline scores < -1 SD on two memory tests predicted AD with 75.91 % accuracy (AUC = 0.80). Only APOE epsilon 4 status further improved prediction (B = 1.10, SE = 0.45, p = .016). A < -1.5 SD cut-off on one test had 66.60 % accuracy (AUC = 0.77). Prediction was further improved using Trails B/A ratio (B = 0.27, SE = 0.13, p = .033), BPF (B = -15.97, SE = 7.58, p = .035), and APOEe4 status (B = 1.08, SE = 0.45, p = .017). A cut-off of < -2 SD on one memory test (AUC = 0.77, SE = 0.03, 95 % CI 0.72-0.82) had 76.52 % accuracy in predicting AD. Trails B/A ratio (B = 0.31, SE = 0.13, p = .017) and APOE epsilon 4 status (B = 1.07, SE = 0.46, p = .019) improved predictive accuracy. Conclusions: Episodic memory impairment in MCI should be defined as scores < -1 SD below normative references on at least two measures. Clinicians or researchers who administer a single test should opt for a more stringent cut-off and collect and analyze whole-brain volume. When feasible, ascertaining APOE epsilon 4 status can further improve prediction.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers
    Brandy L. Callahan
    Joel Ramirez
    Courtney Berezuk
    Simon Duchesne
    Sandra E. Black
    [J]. Alzheimer's Research & Therapy, 7
  • [2] Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease
    Besson, Florent L.
    La Joie, Renaud
    Doeuvre, Loic
    Gaubert, Malo
    Mezenge, Florence
    Egret, Stephanie
    Landeau, Brigitte
    Barre, Louisa
    Abbas, Ahmed
    Ibazizene, Meziane
    de La Sayette, Vincent
    Desgranges, Beatrice
    Eustache, Francis
    Chetelat, Gael
    [J]. JOURNAL OF NEUROSCIENCE, 2015, 35 (29): : 10402 - 10411
  • [3] Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with Alzheimer's disease
    Yasuno, Fumihiko
    Kimura, Yasuyuki
    Ogata, Aya
    Ikenuma, Hiroshi
    Abe, Junichiro
    Minami, Hiroyuki
    Nihashi, Takashi
    Yokoi, Kastunori
    Hattori, Saori
    Shimoda, Nobuyoshi
    Watanabe, Atsushi
    Kasuga, Kensaku
    Ikeuchi, Takeshi
    Takeda, Akinori
    Sakurai, Takashi
    Ito, Kengo
    Kato, Takashi
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2023, 114 : 214 - 220
  • [4] Multimorbidity Is Associated with Preclinical Alzheimer's Disease Neuroimaging Biomarkers
    Mendes, Aline
    du Montcel, Sophie Tezenas
    Levy, Marcel
    Bertrand, Anne
    Habert, Marie-Odile
    Bertin, Hugo
    Dubois, Bruno
    Epelbaum, Stephane
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2018, 45 (5-6) : 272 - 281
  • [5] Neuroimaging Biomarkers for Alzheimer's Disease
    Marquez, Freddie
    Yassa, Michael A.
    [J]. MOLECULAR NEURODEGENERATION, 2019, 14 (1)
  • [6] Neuroimaging biomarkers in Alzheimer's disease
    Nestor, Peter
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [7] Neuroimaging Biomarkers for Alzheimer’s Disease
    Freddie Márquez
    Michael A. Yassa
    [J]. Molecular Neurodegeneration, 14
  • [8] A review of neuroimaging biomarkers of Alzheimer's disease
    Varghese, Tinu
    Sheelakumari, R.
    James, Jija S.
    Mathuranath, P. S.
    [J]. NEUROLOGY ASIA, 2013, 18 (03) : 239 - 248
  • [9] Cognitive Impairment Associated with APOE Biomarkers in Alzheimer's Disease
    Diah, K.
    Vitale, G.
    Keith, M.
    Fornalski, N.
    Golden, C.
    [J]. ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2017, 32 (06) : 668 - 668
  • [10] The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
    Caroli, A.
    Frisoni, G. B.
    [J]. NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1263 - 1274